Search
Cilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Glypromate
go.drugbank.com/drugs/DB05633ExperimentalIn December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … the potential treatment of neurodegenerative diseases by IV infusion.
Aranidipine
go.drugbank.com/drugs/DB09229Experimental[A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate.
Polaprezinc
go.drugbank.com/drugs/DB09221InvestigationalPolaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856].
Synonyms: Zinc L-carnosine, beta-Alanyl-L-histidinato zincInternational brands: Promac-DCasdatifan
go.drugbank.com/drugs/DB21701InvestigationalCasdatifan has a monoisotopic molecular weight of 439.09 Da. … Casdatifan is a small molecule drug. The usage of the INN stem '-tifan' in the name indicates that Casdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor.
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalHyperforin is a phytochemical generated by the plants of the Hypericum family. … One of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.
Afelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Bezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Xamoterol
go.drugbank.com/drugs/DB13781ApprovedXamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. … It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.